- Completed
NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma
Updated: Feb 10
NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in patients with relapsed or refractory multiple myeloma.
Sponsor
Agenus Inc. ( MiNK Therapeutics )
ClinicalTrials.gov Identifier: NCT04754100
Official Title: A PHASE I OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
First Posted : February 15, 2021
Click here for details on ClinicalTrials.gov
Allogeneic Invariant Natural Killer T-cells agenT-797
Allogeneic Invariant Natural Killer T-cells agenT-797 (Code C178501)
AGENT 797
AgenT-797
AGENT-797
agenT797
Allogeneic iNKT agenT-797
- Kentucky: Norton Cancer Institute Louisville
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
Drug: agenT-797
Locations
United States, Kentucky
United States, Massachusetts